Academic Background and Problem Statement In recent years, immune checkpoint inhibitors (ICIs) have made significant progress in cancer treatment, particularly anti-PD-1 and anti-PD-L1 antibodies, which have become the standard of care for first-line treatment in various cancers. However, despite the notable clinical activity of these therapies in ...

TREM2 Deficiency Remodels Intestinal Macrophages and Microbiota to Enhance Anti-PD-1 Tumor Immunotherapy A research team from the Washington University School of Medicine, led by Blanda Di Luccia and other scientists, recently published a study in the journal Science Immunology, revealing how intestinal microbiota and tumor-associated macrophages i...